Twilight Litaka Pharma Limited
Regd. Office : B-22, 'H' BLOCK, MIDC PIMPRI, PUNE-411018

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2012

(Rs.in Lac)

S No.	Particulars	Quarter Ended			Year to Date		Previous Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		30.06.2012	31.03.2012	30.06.2011	30.06.2012	30.06.2011	31.03.2012
1	a. Net Sales / Income From Operations	16033.62	17860.09	18355.99	16033.62	18355.99	72953.71
	b. Other Operating Income			-		-	
2	Expenditure						
	a Increase/decrease in stock in trade & WIP	49.78	-141.08	-170.21	49.78	-170.21	-281.24
	b Consumption of Raw material	7717.23	1505.18	12867.11	7717.23	12867.11	40055.87
	c Purchase of traded goods.	4891.26	12931.22	1357.29	4891.26	1357.29	16402.58
	d Employee cost	453.76	452.78	477.57	453.76	477.57	1982.39
	e Depreciation	135.96	127.68	104.29	135.96	104.29	510.25
	f Other expenditure	1067.99	1224.12	1029.46	1067.99	1029.46	4661.34
	g Expenditure (a to f)	14315.98	16099.91	15665.51	14315.98	15665.51	63331.20
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	1717.64	1760.18	2690.48	1717.64	2690.48	9622.51
4	Other Income	20.29	255.11	21.49	20.29	21.49	332.60
5	**Profit before Interest & Exceptional Items (3+4)**	1737.93	2015.29	2711.97	1737.93	2711.97	9955.11
6	Interest	1449.13	1232.12	983.61	1449.13	983.61	4698.28
7	**Profit after Interest, but before Exceptional Items (5-6)**	288.80	783.17	1728.36	288.80	1728.36	5256.83
8	Exceptional Items	-	-	-	-	-	-
9	**Profit from Ordinary Activities before tax (7+8)**	288.80	783.17	1728.36	288.80	1728.36	5256.83
10	Tax Expenses	75.00	90.00	446.00	75.00	446.00	1360.00
11	**Profit from Ordinary Activities after tax (9-10)**	213.80	693.17	1282.36	213.80	1282.36	3896.83
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	**Net Profit for the period**	213.80	693.17	1282.36	213.80	1282.36	3896.83
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1239.06	1239.06	1239.06	1239.06	1239.06
15	Reserve excluding revaluation reserves	19640.84	19427.04	17278.00	19640.84	17278.00	19427.04
16	Earning per share (EPS)						
	a. Basic and diluted EPS before extraordinary items for the period	*0.86	*2.75	*5.85	*0.86	*5.85	*16.19
	b. Basic and diluted EPS after extraordinary items for the period.	*0.86	*2.75	*5.85	*0.86	*5.85	*16.19
17	Aggregate of non promoter shareholding						
	number of shares	23520796	23520796	19402859	23520796	19402859	23520796
	percentage of shareholding	94.91	94.91	78.30	94.91	78.30	94.91
18	Promoters and Promoters Group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	1236247	1236247	5047845	1236247	5047845	1236247
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	98.07	98.07	93.85	98.07	93.85	98.07
	- Percentage of shares (as % to the total share capital of the Company)	4.99	4.99	20.37	4.99	20.37	4.99
	b) Non Encumbered						
	- Number of shares	24242	24242	330581.00	24242	330581.00	24242
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	1.93	1.93	6.15	1.93	6.15	1.93
	- Percentage of shares (as % to the total share capital of the Company)	0.10	0.10	1.33	0.10	1.33	0.10

* not annualised

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th August, 2012.

2] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "'Segment Reporting" is considered to be the only business segment.

3] The financial results for the quarter ended 30th June,2012 of the company are prepared on standalone basis.

4] The above results were subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

5] On receipt of appoval from Bankers of the company, the dividend which was declared in the last Annual General Meeting held on 29th September,2011 will be paid to the shareholders of the company

6] Previous year's figures have been regrouped and rearranged wherever necessary.

7] During the Current Quarter Two (2) Investors complaints were received. Therewere Thireteen (13) Investors Complaints pending at the beginning of the Quarter and Fifteen (15) Investors Complaints pending at the end of the Quarter.

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

TWILIGHT LITAKA PHARMA LTD. PUNE

Place : Pune
Date : 14th August, 2012